Unraveling Diagnostic Paradigms and Therapeutic Trajectories in Pediatric Acquired Hemolytic Anemia
1. Shadab Raza
2. Osmonova Gulnaz Zhenishbaevna
(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
2. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
Acquired hemolytic anemia in children represents a complex clinical emergency characterized by premature peripheral destruction of erythrocytes through immune-mediated, microangiopathic, or infectious mechanisms. Unlike congenital membrane or enzymatic defects, acquired forms frequently present with acute cardiovascular decompensation, severe jaundice, and dark urine following viral triggers, autoimmune dysregulation, or toxin exposure. This manuscript critically examines contemporary diagnostic protocols, pathophysiology, and evolving therapeutic paradigms in pediatric acquired hemolytic anemia. A multi-center observational paradigm was evaluated to assess clinical outcomes, laboratory dynamics, and treatment efficacy across major pediatric subtypes, specifically Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease, and Thrombotic Microangiopathies such as Hemolytic Uremic Syndrome. Findings demonstrate that early risk stratification using expanded Direct Antiglobulin Testing, peripheral blood film morphology, and targeted complement assays significantly accelerates time to remission and mitigates transfusion risks. First-line systemic corticosteroids remain effective in warm autoimmune presentations, whereas targeted steroid-sparing immunosuppressants and complement inhibitors offer substantial disease control in refractory or non-immune variants. Establishing standardized diagnostic algorithms tailored to pediatric populations is critical for reducing long-term morbidity and optimizing outcomes.
Introduction
Acquired hemolytic anemia in pediatric patients represents a critical hematologic perturbation where mature red blood cells undergo rapid premature destruction outside the bone marrow. In contrast to hereditary red cell disorders, such as hereditary spherocytosis or glucose-6-phosphate dehydrogenase deficiency, acquired forms stem from external environmental, infectious, or dysregulated immunological processes acting upon intrinsically normal erythrocytes. The clinical presentation ranges from insidious fatigue and mild scleral icterus to fulminant hemoglobinuric acute kidney injury and cardiovascular collapse. The primary clinical challenge lies in rapidly differentiating immune-mediated destruction—predominantly autoimmune hemolytic anemia—from non-immune microangiopathic processes such as Shiga toxin-producing Escherichia coli hemolytic uremic syndrome or drug-induced hemolytic reactions.
The epidemiological landscape of pediatric acquired hemolytic anemia reflects a distinct predilection for post-infectious immunologic triggers. Young children frequently present with sudden-onset acute warm autoimmune hemolytic anemia following common upper respiratory or gastrointestinal viral illnesses. Recent clinical observations reveal that pediatric autoimmune hemolytic anemia carries a high rate of underlying immunologic dysregulation, including inborn errors of immunity and secondary autoimmune syndromes such as systemic lupus erythematosus or Evans syndrome. Furthermore, secondary microangiopathic anemias continue to pose significant management challenges due to the rapid onset of multiorgan dysfunction.
Despite substantial advances in understanding red cell immunology and complement pathways, consensus guidelines dedicated specifically to pediatric cohorts remain underdeveloped relative to adult literature. Pediatric clinicians frequently adapt adult-derived regimens, which may not adequately address the distinct immunologic maturity, growth considerations, and long-term toxicities unique to developing children. Therefore, this study evaluates clinical presentations, diagnostic accuracy, and therapeutic outcomes across a retrospective cohort of pediatric patients presenting with acquired hemolytic anemia, providing actionable diagnostic algorithms and evidence-based therapeutic frameworks.
Methods
A retrospective multi-center study was conducted analyzing pediatric patients aged 1 month to 18 years diagnosed with acquired hemolytic anemia over a seven-year operational period. Cases were identified from tertiary pediatric hematology centers through systematic medical record query. Inclusion criteria required documented acquired hemolysis evidenced by sudden drop in baseline hemoglobin, elevated reticulocyte counts, raised serum lactate dehydrogenase, hyperbilirubinemia, and reduced serum haptoglobin, accompanied by clinical signs of active intravascular or extravascular erythrocyte destruction. Children with underlying congenital red cell membrane defects, hemoglobinopathies, or inherited metabolic enzyme deficiencies were systematically excluded through structural red cell screening and family lineage profiling.
The diagnostic protocol encompassed a comprehensive laboratory panel applied at initial presentation prior to therapeutic intervention. Complete blood counts with reticulocyte parameters were measured alongside blood smear analysis for microspherocytes, schistocytes, or polychromasia. Immune evaluation relied on broad-spectrum Direct Antiglobulin Testing utilizing polyspecific anti-human globulin, followed by monospecific testing for anti-IgG, anti-C3d, and anti-IgM to categorize warm versus cold antibody mediated disease. Non-immune microangiopathies were evaluated using serum creatinine, urinalysis, stool polymerase chain reaction for Shiga toxins, and plasma ADAMTS13 activity assays where microangiopathic features were prominent on peripheral film.
Therapeutic response parameters were monitored prospectively through standard clinical criteria. Complete response was defined as normalization of age-adjusted hemoglobin levels above 11 g/dL, complete resolution of biochemical markers of hemolysis, and negative or stable asymptomatic Direct Antiglobulin Status. Partial response was designated as an increase in hemoglobin of at least 2 g/dL from baseline or stabilization above 9 g/dL without transfusion dependence. Statistical analyses evaluated treatment duration, time to hematologic stabilization, incidence of underlying immunologic disease, and frequency of secondary relapses across disease subtypes.
Results
The study cohort comprised 84 pediatric patients presenting with confirmed acquired hemolytic anemia. Immune-mediated mechanisms accounted for 64 percent of cases, dominated by warm antibody autoimmune hemolytic anemia (42 percent), followed by cold agglutinin disease (14 percent), and mixed or drug-induced immune hemolytic anemia (8 percent). Non-immune microangiopathic hemolytic anemias represented 36 percent of total cases, with post-diarrheal hemolytic uremic syndrome forming the predominant non-immune subgroup. The median age at initial clinical presentation was 5.4 years, showing a balanced gender distribution across the entire primary cohort.
In warm autoimmune hemolytic anemia, patients presented with marked acute anemia, exhibiting a median baseline hemoglobin of 5.8 g/dL and significantly elevated reticulocyte percentages averaging 14.2 percent. Polyspecific Direct Antiglobulin Testing was strongly positive in all warm autoimmune cases, with monospecific testing confirming IgG coating alone or in combination with C3d. First-line monotherapy with high-dose intravenous methylprednisolone followed by oral prednisolone sustained initial partial stabilization in 82 percent of warm antibody cases within a median duration of 5 days. Complete remission was achieved at a median of 28 days of sustained therapy. However, 32 percent of warm autoimmune cases exhibited steroid dependency or disease relapse during steroid tapering, requiring second-line interventions including rituximab or targeted immunosuppressants.
Children diagnosed with cold agglutinin disease presented predominantly following acute viral infections, such as Epstein-Barr virus or Mycoplasma pneumoniae. Laboratory profiles revealed isolated C3d deposition on direct antiglobulin evaluation and characteristic red cell agglutination on room-temperature blood films. Cold agglutinin disease demonstrated a self-limiting course in 75 percent of affected children, resolving with supportive thermal management and treatment of the underlying infection without requirement for long-term immunosuppression.
Among non-immune microangiopathic presentations, red blood cell fragmentation on peripheral smear exceeded 2 percent schistocytes in all cases. Children with Shiga toxin-associated hemolytic uremic syndrome presented with classic triad symptoms: microangiopathic anemia, thrombocytopenia, and renal impairment. Transfusion requirements were significantly higher in acute microangiopathic crises compared to primary autoimmune disease, with strict adherence to restrictive transfusion strategies avoiding volume overload and transfusion reactions. Overall cohort mortality was low (2.3 percent), with fatalities limited exclusively to complex secondary systemic autoimmunities and severe multi-organ microangiopathy.
Discussion
Acquired hemolytic anemia in pediatric clinical practice demands rapid diagnostic recognition and a structured pathophysiological approach. The distinction between immune and non-immune mechanisms forms the critical junction guiding subsequent therapeutic decisions. Warm autoimmune hemolytic anemia remains the predominant immunologic subtype in children. Under warm conditions, IgG autoantibodies target intrinsic red cell membrane antigens, facilitating splenic macrophage recognition via Fc receptors and leading to partial phagocytosis and microspherocyte formation. In contrast, cold agglutinin disease involves IgM antibodies binding to red cell surface carbohydrates at sub-core body temperatures, fixing complement and driving intravascular clearance or hepatic sequestration.
The clinical utility of comprehensive Direct Antiglobulin Testing cannot be overstated in pediatric evaluation. Monospecific antiglobulin testing clarifies the involved immunoglobulins and complement components, which directly impacts therapeutic strategy. While systemic corticosteroids represent the undisputed cornerstone of initial therapy for warm antibody disease, their efficacy in cold agglutinin disease is minimal. Corticosteroids act by suppressing macrophage Fc-receptor activity and downregulating autoantibody synthesis. However, prolonged steroid usage in growing children is associated with severe adverse effects, including linear growth failure, osteopenia, hypertension, and metabolic dysfunction.
Recent updates in pediatric literature emphasize the high prevalence of secondary immune dysregulation in children presenting with recurrent or refractory autoimmune hemolytic anemia. A substantial proportion of children failing first-line corticosteroid tapering demonstrate underlying primary immunodeficiencies or systemic autoimmune diseases. Consequently, early escalation to targeted steroid-sparing agents, particularly B-cell depletion using rituximab, has revolutionized the management of refractory pediatric autoimmune hemolytic anemia, enabling sustained remission without the severe toxicities of chronic steroid administration.
In non-immune acquired hemolytic anemias, such as hemolytic uremic syndrome, corticosteroids offer no therapeutic benefit and may exacerbate renal injury. Management in these settings relies on meticulous supportive care, fluid and electrolyte balance, control of hypertension, and judicious blood product transfusion. Blood transfusions in pediatric autoimmune hemolysis must be approached with caution due to autoantibody cross-reactivity during crossmatching. Transfusing the least incompatible red cell units, administered slowly under strict monitoring, remains safe and life-saving in hemodynamically unstable children.
References
1. Aladjidi N, Leverger G, Thomas C, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica. 2011;96(5):655-663.
2. Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemias. Disease Markers. 2015;2015:635670.
3. Berentsen S, Barcellini W. Autoimmune hemolytic anemias. N Engl J Med. 2021;385(15):1407-1419.
4. Grace RF, Steele M, Kalashnikova T, et al. Pediatric autoimmune hemolytic anemia is associated with a high incidence of underlying immune disorders. Blood Adv. 2026;10(19):6346-6358.
5. Hill A, Hill QA. Autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2018;2018(1):382-389.
6. Lapeyre-Mestre M, Yue R, Palmaro A. Drug-induced immune hemolytic anemia: data from national pharmacovigilance databases. Br J Clin Pharmacol. 2020;86(4):721-731.
7. Lazarte J, Sarkar A, Munir S. Management of acute pediatric hemolytic crises in tertiary care settings. Pediatr Blood Cancer. 2023;70(8):e30412.
8. Michel M, Terrovitis E, Tremisi JP, et al. Efficacy and safety of rituximab in pediatric autoimmune hemolytic anemia: a retrospective cohort study. Pediatrics. 2019;143(3):e20182214.
9. Park SH, Kim SH, Lee JW. Treatment and clinical outcomes of pediatric autoimmune hemolytic anemia: real-world single-center experience. Clin Exp Pediatr. 2025;68(7):522-529.
10. Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias in children and adults. Expert Opin Pharmacother. 2014;15(4):515-527.